Visible Genetics Gearing Up For TruGene HIV-1 Genotyping Kit Roll-Out
This article was originally published in The Gray Sheet
Executive Summary
Visible Genetics has locked up 25% of the U.S. HIV genotyping market with its TruGene HIV-1 genotyping kit, company officials remarked during a Feb. 24 teleconference.
You may also be interested in...
Visible Genetics Trugene
HIV-1 genotyping kit 510(k) submission to FDA is delayed by approximately three months as the firm conducts an additional study involving laboratory-constructed molecular infectious clones (MICs) rather than samples drawn from HIV infected patients, used in previous studies. The Toronto-based company previously had predicted a submission in the first half of 2000 (1"The Gray Sheet" March 6, p. 12). The study is scheduled for completion "in the coming weeks," and the submission will be made in the third quarter, making the kit "the first ever sequencing-based diagnostic test submitted to the FDA for approval," the company says
Visible Genetics Trugene
HIV-1 genotyping kit 510(k) submission to FDA is delayed by approximately three months as the firm conducts an additional study involving laboratory-constructed molecular infectious clones (MICs) rather than samples drawn from HIV infected patients, used in previous studies. The Toronto-based company previously had predicted a submission in the first half of 2000 (1"The Gray Sheet" March 6, p. 12). The study is scheduled for completion "in the coming weeks," and the submission will be made in the third quarter, making the kit "the first ever sequencing-based diagnostic test submitted to the FDA for approval," the company says
HIV Genotyping Drug Resistance Assays Should Be Downclassified - Panel
Downclassification of HIV genotyping drug resistance assays with special controls would serve the public health interest and "be of use to every AIDS patient in the lifetime of their illness," FDA staffers asserted Sept. 17 before the Blood Products Advisory Committee.